Gilead Sciences (GILD) 91.46 $GILD
$1,000 pill now hepatitis C treatment of choice
By RICARDO ALONSO-ZALDIVAR - AP - Tue Jul 29, 2:11AM CDT
WASHINGTON (AP) — A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
Final Glance: Biotechnology companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Midday Glance: Biotechnology companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Gilead Sciences (GILD) Approaches New Upside Target of $91.85
Comtex SmarTrend(R) - Mon Jul 28, 10:14AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.77 today and has reached the first level of resistance at $90.85. Investors may be interested in a cross of the next upside pivot targets of $91.85 and $93.93.
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Jul 28, 10:02AM CDT
Gilead Sciences (GILD) price target was raised to $127 by analysts at Maxim Group on Monday.
Early Glance: Biotechnology companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
Uptrend Call Working As Gilead Sciences Stock Rises 24.0% (GILD)
Comtex SmarTrend(R) - Fri Jul 25, 9:17AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 23.99% as of today's recent price of $89.96.
Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 25, 7:30AM CDT
Gilead Sciences is finally an oncology company. It's been years in the making . On Wednesday, the biotech got Zydelig approved to treat three different B-cell blood cancers: chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma,...
European CHMP Adopts Positive Opinion for Gilead's Zydelig(R) (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Jul 25, 6:24AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Zydelig(R) (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin lymphoma (iNHL). The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).
Why Gilead Sciences, inc. Stock Was Flat Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:07PM CDT
Gilead Sciences turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter. The difference in earnings was even starker: Adjusted EPS of $2.36...
$1,000 pill now hepatitis C treatment of choice
By RICARDO ALONSO-ZALDIVAR - AP - Tue Jul 29, 2:11AM CDT
WASHINGTON (AP) — A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
Final Glance: Biotechnology companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Midday Glance: Biotechnology companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Gilead Sciences (GILD) Approaches New Upside Target of $91.85
Comtex SmarTrend(R) - Mon Jul 28, 10:14AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.77 today and has reached the first level of resistance at $90.85. Investors may be interested in a cross of the next upside pivot targets of $91.85 and $93.93.
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Jul 28, 10:02AM CDT
Gilead Sciences (GILD) price target was raised to $127 by analysts at Maxim Group on Monday.
Early Glance: Biotechnology companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
Uptrend Call Working As Gilead Sciences Stock Rises 24.0% (GILD)
Comtex SmarTrend(R) - Fri Jul 25, 9:17AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 23.99% as of today's recent price of $89.96.
Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 25, 7:30AM CDT
Gilead Sciences is finally an oncology company. It's been years in the making . On Wednesday, the biotech got Zydelig approved to treat three different B-cell blood cancers: chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma,...
European CHMP Adopts Positive Opinion for Gilead's Zydelig(R) (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Jul 25, 6:24AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Zydelig(R) (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin lymphoma (iNHL). The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).
Why Gilead Sciences, inc. Stock Was Flat Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:07PM CDT
Gilead Sciences turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter. The difference in earnings was even starker: Adjusted EPS of $2.36...
